ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.56−0.07 (-0.51%)
Close on Nov 18, 2026Market cap $3.04BP/E 19.4Yield –
ADMA Biologics total assets
Total assets on the balance sheet at the end of each period.
ADMA Biologics's total assets was $684.21M at Jun 30, 2026. For fiscal 2025 it was $624.24M, up 27.7% from the year before. Over ten years it grew 38.7% a year on average. The highest annual figure on record is $624.24M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $624.24M | +27.7% |
| FY2024 | Dec 31, 2024 | $488.68M | +48.5% |
| FY2023 | Dec 31, 2023 | $329.18M | -5.5% |
| FY2022 | Dec 31, 2022 | $348.46M | +26.1% |
| FY2021 | Dec 31, 2021 | $276.25M | +33.0% |
| FY2020 | Dec 31, 2020 | $207.67M | +63.4% |
| FY2019 | Dec 31, 2019 | $127.09M | +43.0% |
| FY2018 | Dec 31, 2018 | $88.88M | -17.7% |
| FY2017 | Dec 31, 2017 | $108.02M | +356.1% |
| FY2016 | Dec 31, 2016 | $23.69M | -0.1% |
| FY2015 | Dec 31, 2015 | $23.71M | -12.2% |
| FY2014 | Dec 31, 2014 | $27.02M | -15.5% |
| FY2013 | Dec 31, 2013 | $31.98M | +105.6% |
| FY2012 | Dec 31, 2012 | $15.56M | +431.6% |
| FY2011 | Dec 31, 2011 | $2.93M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $684.21M | +22.5% |
| Q1 FY2026 | Mar 31, 2026 | $665.18M | +30.3% |
| Q4 FY2025 | Dec 31, 2025 | $624.24M | +27.7% |
| Q3 FY2025 | Sep 30, 2025 | $568.69M | +45.6% |
| Q2 FY2025 | Jun 30, 2025 | $558.38M | +48.3% |
| Q1 FY2025 | Mar 31, 2025 | $510.57M | +45.5% |
| Q4 FY2024 | Dec 31, 2024 | $488.68M | +48.5% |
| Q3 FY2024 | Sep 30, 2024 | $390.62M | +11.9% |
| Q2 FY2024 | Jun 30, 2024 | $376.40M | +9.7% |
| Q1 FY2024 | Mar 31, 2024 | $350.88M | +3.0% |
| Q4 FY2023 | Dec 31, 2023 | $329.18M | -5.5% |
| Q3 FY2023 | Sep 30, 2023 | $349.00M | +16.1% |
| Q2 FY2023 | Jun 30, 2023 | $343.03M | +15.5% |
| Q1 FY2023 | Mar 31, 2023 | $340.79M | +10.6% |
| Q4 FY2022 | Dec 31, 2022 | $348.46M | +26.1% |
| Q3 FY2022 | Sep 30, 2022 | $300.56M | +25.9% |
| Q2 FY2022 | Jun 30, 2022 | $296.93M | +27.5% |
| Q1 FY2022 | Mar 31, 2022 | $308.03M | +30.7% |
| Q4 FY2021 | Dec 31, 2021 | $276.25M | +33.0% |
| Q3 FY2021 | Sep 30, 2021 | $238.64M | +25.6% |
| Q2 FY2021 | Jun 30, 2021 | $232.81M | +21.5% |
| Q1 FY2021 | Mar 31, 2021 | $235.67M | +11.9% |
| Q4 FY2020 | Dec 31, 2020 | $207.67M | +63.4% |
| Q3 FY2020 | Sep 30, 2020 | $189.98M | +37.9% |
| Q2 FY2020 | Jun 30, 2020 | $191.54M | +33.7% |
| Q1 FY2020 | Mar 31, 2020 | $210.52M | +169.5% |
| Q4 FY2019 | Dec 31, 2019 | $127.09M | +43.0% |
| Q3 FY2019 | Sep 30, 2019 | $137.78M | +29.6% |
| Q2 FY2019 | Jun 30, 2019 | $143.27M | +21.7% |
| Q1 FY2019 | Mar 31, 2019 | $78.12M | -14.3% |
| Q4 FY2018 | Dec 31, 2018 | $88.88M | -17.7% |
| Q3 FY2018 | Sep 30, 2018 | $106.35M | +46.1% |
| Q2 FY2018 | Jun 30, 2018 | $117.75M | +39.1% |
| Q1 FY2018 | Mar 31, 2018 | $91.14M | +418.0% |
| Q4 FY2017 | Dec 31, 2017 | $108.02M | +356.1% |
| Q3 FY2017 | Sep 30, 2017 | $72.81M | +164.8% |
| Q2 FY2017 | Jun 30, 2017 | $84.64M | – |
| Q1 FY2017 | Mar 31, 2017 | $17.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.69M | – |
| Q3 FY2016 | Sep 30, 2016 | $27.50M | – |
See a number that looks wrong?